MDM2 and fibrosarcoma: Similar alterations of splicing of MDM2 were also observed in MDA-MB-231 (breast adenosarcoma), BT549 (breast carcinoma), HT1080 (fibrosarcoma), RD (rhabdomyosarcoma), MG-63 (osteosarcoma), MSU (fibrobastic cell line) and HDF1 and 2 (primary dermal fibroblasts) cells treated with 50 μM cisplatin for 24 hours (Figure 1F).